



**Comparative Study of Local Recurrence in  
HER2 Neu +ve Breast Cancer Between Patients  
Treated with Breast Conserving Surgery and  
Modified Radical Mastectomy**

*Thesis*

Submitted for Partial Fulfillment of the Master  
Degree in General Surgery

*By*

**Mario Atef Shafik**

M.B.B.Ch, Faculty of Medicine, Mansoura University

*Under Supervisors*

**Prof. Dr. Osama Ali El- Atrash**

Professor of General Surgery  
Faculty of Medicine – Ain Shams University

**Prof. Dr. Mohamed El-Sayed El-Shinawi**

Professor of General Surgery  
Faculty of Medicine – Ain Shams University

**Prof. Dr. Ahmed Gamal-El Din Osman**

Professor of General Surgery  
Faculty of Medicine – Ain Shams University

**Faculty of Medicine  
Ain Shams University  
2018**



## ACKNOWLEDGEMENT

First of all, thanks to **Allah** whose magnificent help was the main factor in completing this work.

No words could express my deepest thanks and appreciation to **Prof. Dr. Osama Ali El- Atrash**, Professor of General Surgery, Faculty of Medicine, Ain Shams University, for inspiring me with the idea of this work. His patience, precious advice and guidance enlightened my way throughout this work.

I want also to express my profound gratitude to **Prof. Dr. Mohamed El-Sayed El-Shinawi**, Professor of General Surgery, Faculty of Medicine, Ain Shams University, for his patience, valuable advice and continuous help in completing this work.

I am also deeply indebted to **Prof. Dr. Ahmed Gamal-El Din Osman**, Assistant Professor of General Surgery, Faculty of Medicine, Ain Shams University, for his kind help, guidance, useful advices, continuous encouragement and support all through my entire work.

Finally, my deepest thanks to all my family and colleagues who helped me in the production of this work.

# Contents

Subjects	Page
List of abbreviations.....	II
List of figures.....	V
List of tables.....	VIII
• <b>Introduction</b> .....	1
• <b>Aim of the Work</b> .....	4
• <b>Review of Literature</b>	
♦ <b>Chapter (1): Anatomy of the Breast</b> .....	5
♦ <b>Chapter (2): Pathology of Breast Cancer</b> .....	18
♦ <b>Chapter (3): Biological Behavior of Cancer         Breast</b> .....	47
♦ <b>Chapter (4): Diagnosis of Cancer Breast</b> .....	69
♦ <b>Chapter (5): Treatment of Cancer Breast</b> .....	92
• <b>Patients and Methods</b> .....	128
• <b>Results</b> .....	131
• <b>Discussion</b> .....	147
• <b>Conclusion</b> .....	154
• <b>Summary</b> .....	155
• <b>References</b> .....	157
• <b>Arabic Summary</b>	

## **List of Abbreviations**

<i>Abbreviation</i>	<i>Meaning</i>
<b>3D</b>	Three dimensional image reconstruction
<b>ACBS</b>	American college of breast surgeons
<b>ACOG</b>	American college of Obstetricians and Gynecologists
<b>AIS</b>	Aromatase inhibitors
<b>APBI</b>	Accilirated partial breast irradiation
<b>ASCO</b>	American society of clinical oncology
<b>BL1</b>	Basal like 1
<b>BL2</b>	Basal like 2
<b>BLIA</b>	Basal like immune activated
<b>BLIS</b>	Basal like immune suppressed
<b>BSE</b>	Breast self exam
<b>CBE</b>	Clinical breast exam
<b>CDK</b>	Cytidine dependent kinase
<b>CEA</b>	Carcino Empryonic Antigen
<b>CML</b>	Chronic myeloid leukemia
<b>CPM</b>	Contralateral prophylactic mastectomy
<b>CT</b>	Compund tomography
<b>DCIS</b>	Ductal Carcinoma Insitu
<b>DFS</b>	Dissease free syrival

### *List of Abbreviations*

---

<i>Abbreviation</i>	<i>Meaning</i>
<b>DIEP</b>	Deep inferior epigastric perforator
<b>DMI</b>	Dereviative of the microtubule
<b>EFS</b>	Event free survival
<b>EGFR</b>	Endothelial growth factor
<b>ER</b>	Estrogen receptor
<b>FEA</b>	Feature
<b>FISH</b>	Fluorescent insitu hypiridization
<b>FNAB</b>	Fine needle aspiration biobsy
<b>FTIS</b>	Farnesyltransferase inhibitor
<b>H&amp;E</b>	Hematoxylin and eosin
<b>HER</b>	Human epidermal growth factor
<b>HSP90</b>	Heat shock protein 90
<b>IBC</b>	Inflammatory breast cancer
<b>IDC</b>	Iniltrating Ductal Carcinoma
<b>IHE</b>	Immunohistochemistry
<b>ILC</b>	Infiltrating Lobular Carcinoma
<b>IM</b>	Immunomodularity
<b>LAR</b>	Luminal androgen receptor subtype
<b>LCIS</b>	Lobular Carcinoma Insitu
<b>LGASC</b>	Low grade adenosquamous carcinoma
<b>M</b>	Mesenchymal
<b>MBA</b>	Monoclonal antibody

## *List of Abbreviations*

---

<i>Abbreviation</i>	<i>Meaning</i>
<b>MRI</b>	Magnetic resonance imaging
<b>MSL</b>	Mesenchymal stem like
<b>MTOR</b>	Mammalian target o rabamycin
<b>NAC</b>	Nipple areolar complex
<b>NSM</b>	Nipple sparing mastectomy
<b>NST</b>	Non specific type
<b>OS</b>	Overall syrival
<b>PARP</b>	Poly adenosine diphosphate ribose polymerase
<b>PCR</b>	Pathological complete response
<b>PET</b>	Positron emission tomography
<b>PMRT</b>	Post mastectomy radiotheraby
<b>ROR</b>	Risk o recurrence
<b>RT</b>	Radiotherapy
<b>Rt-pcr</b>	Real time polymerase chain reaction
<b>SLN</b>	Sentinel lymph node
<b>SSM</b>	Skin sparing mastectomy
<b>SSRIS</b>	Selectve serotonin reuptake inhibitors
<b>TC</b>	Tubular carcinoma
<b>TKIS</b>	Tyrosine kinase inhibitors
<b>TN</b>	Triple negative

## *List of Abbreviations*

---

<i>Abbreviation</i>	<i>Meaning</i>
<b>TRAM</b>	Transverse rectus abdominus myococutaneous
<b>US</b>	Ultrasound
<b>USPSTF</b>	US preventive service task orce
<b>VEGF</b>	Vascular endothelial growth factor
<b>VEGFR</b>	Vascular endothelial cell growth factor receptor

## **List of Figures**

<b><u>No.</u></b>	<b><u>Figure</u></b>	<b><u>Page</u></b>
<b><u>1</u></b>	Milk line of the breast.	<b>6</b>
<b><u>2</u></b>	Anatomy of the breast.	<b>10</b>
<b><u>3</u></b>	Duct system of the breast.	<b>11</b>
<b><u>4</u></b>	Blood supply of the breast.	<b>12</b>
<b><u>5</u></b>	Venous drainage of the breast.	<b>13</b>
<b><u>6</u></b>	Sensory innervation of the breast.	<b>14</b>
<b><u>7</u></b>	Lymphatic drainage of the breast.	<b>17</b>
<b><u>8</u></b>	DCIS of high nuclear grade.	<b>25</b>
<b><u>9</u></b>	DCIS of low nuclear grade.	<b>25</b>
<b><u>10</u></b>	Tubular carcinoma. Tumor cells form tubules, some of which have microcalcifications in their lumens.	<b>33</b>
<b><u>11</u></b>	Intrinsic subtype identification using the PAM50 subtype predictor.	<b>51</b>
<b><u>12</u></b>	Comparison between studied groups as regard age.	<b>132</b>
<b><u>13</u></b>	Comparison between studied groups as regard pathological tumor size diameter.	<b>134</b>
<b><u>14</u></b>	Comparison between studied groups as regard Histological type.	<b>136</b>
<b><u>15</u></b>	Comparison between studied groups as regard number of LNS.	<b>138</b>
<b><u>16</u></b>	Comparison between studied groups as regard hormonal therapy.	<b>140</b>



## *List of Figures*

---

<b><u>No.</u></b>	<b><u>Figure</u></b>	<b><u>Page</u></b>
<b><u>17</u></b>	Comparison between studied groups as regard adjuvant systemic therapy.	<b>142</b>
<b><u>18</u></b>	Comparison between studied groups as regard herceptin.	<b>144</b>
<b><u>19</u></b>	Comparison between studied groups as regard Interval to local (recurrence) (years).	<b>146</b>

## **List of Tables**

<b><u>No.</u></b>	<b><u>Table</u></b>	<b><u>Page</u></b>
<b><u>1</u></b>	Primary tumor of cancer breast in TNM.	<b>39</b>
<b><u>2</u></b>	Lymph node involvement of cancer breast in TNM.	<b>40</b>
<b><u>3</u></b>	Distant metastasis of cancer breast in TNM.	<b>40</b>
<b><u>4</u></b>	Anatomic stage/prognostic group of cancer breast in TNM.	<b>40</b>
<b><u>5</u></b>	Comparison between studied groups as regard age.	<b>131</b>
<b><u>6</u></b>	Comparison between studied groups as regard pathological tumor size diameter.	<b>133</b>
<b><u>7</u></b>	Comparison between studied groups as regard Histological type.	<b>135</b>
<b><u>8</u></b>	Comparison between studied groups as regard number of LNS.	<b>137</b>
<b><u>9</u></b>	Comparison between studied groups as regard hormonal therapy.	<b>139</b>
<b><u>10</u></b>	Comparison between studied groups as regard adjuvant systemic therapy and radiotherapy.	<b>141</b>
<b><u>11</u></b>	Comparison between studied groups as regard herceptin.	<b>143</b>
<b><u>12</u></b>	Comparison between studied groups as regard Interval to local recurrence (years).	<b>145</b>

## Introduction

Cancer breast is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012 (second most common cancer overall after lung cancer). This represents about 12% of all new cancer cases and 25% of all cancers in women. It is the fifth most common cause of death from cancer in women. (1) In Egypt, breast cancer accounts for 37% of women's cancer with an incidence rate of 49.6/100,000.2. (2)

In 1894, Halsted developed Radical mastectomy in which the breast is completely removed, including the nipple. The surgeon also removes the overlying skin, the muscles beneath the breast, and the lymph nodes. This led to serious disfigurement and psychic trauma to the patients. So, Patey and WH Dyson developed Modified Radical Mastectomy which is a less traumatic and more widely used procedure. The entire breast is removed as well as the underarm lymph nodes. But chest muscles are left intact.

In 1927 Keynes developed breast conserving surgery which is to remove the cancer leaving as much intact of the breast as possible. (3)

Although survival rates with BCT are equivalent to mastectomy, local recurrence after BCT is higher than after

mastectomy (4). The studies showed that there was no significant difference in the survival and recurrence rate between the breast-conserving surgery plus radiation therapy and traditional modified radical surgery for early-stage breast cancer patients (5).

More than 10 years ago, gene expression profiling based on DNA microarray revealed the molecular heterogeneity of BC (6). A new molecular classification was defined, dividing BC in at least 5 biologically and clinically relevant subtypes: luminal A (LA), luminal B (LB), basal-like (BL), HER2-enriched and normal-like (NL). These subtypes are linked to major molecular alterations such as HR and HER2 expression and proliferation and to mammary cell types. (7)

During patient follow up, it was noticed that HR positive patients experienced more cancer relapse in the first 5 years than HR-negative patients. Interestingly, patients with HR-negative tumours were less likely to experience first recurrence in bone and more likely to recur in brain, compared to patients with hormone receptor-positive tumours. (8)



Studies showed that there was a lower local recurrence rate following mastectomy compared to breast conservative treatment for Luminal and HER2/neu-overexpressing tumors. (9)



## **Aim of the Work**

To determine the prognosis of HER2 +ve neu breast cancer regarding local recurrence in patients treated with breast conservative surgery vs Modified Radical Mastectomy.

## *Chapter (1)*

# **Anatomy of the Breast**

### **Anatomy:**

### **Embryology and Functional Anatomy of the Breast:**

#### **Embryology:**

At the fifth or sixth week of fetal development, two ventral bands of thickened ectoderm (mammary ridges, milk lines) are evident in the embryo.<sup>16</sup> In most mammals, paired breasts develop along these ridges, which extend from the base of the forelimb (future axilla) to the region of the hind limb (inguinal area). These ridges are not prominent in the human embryo and disappear after a short time, except for small portions that may persist in the pectoral region. (10)

Accessory breasts (polymastia) or accessory nipples (polythelia) may occur along the milk line when normal regression fails. Each breast develops when an ingrowth of ectoderm forms a primary tissue bud in the mesenchyme. The primary bud, in turn, initiates the development of 15 to 20 secondary buds. Epithelial cords develop from the secondary buds and extend into the surrounding